Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced multiple oral and poster presentations, including a late-breaking oral presentation of avutometinib and defactinib combination from the RAMP 201 Part A trial in heavily pretreated patients with low-grade serous ovarian cancer (LGSOC), at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, to be held on March 16-18 in San Diego, California. Verastem will have an exhibition booth (#420) at the meeting to provide an overview of its ongoing cancer research.

“Important subgroup analyses from Part A of the Phase 2 RAMP 201 clinical trial evaluating avutometinib and defactinib demonstrate how our research in low-grade serous ovarian cancer continues to elucidate the potential use of this combination in a heavily pretreated patient population, including patients who received a prior MEK-only inhibitor,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “In addition, the plenary oral presentation highlighting preclinical efficacy of avutometinib in combination with a FAK inhibitor reinforces the potential of this combination in low-grade serous ovarian cancer regardless of KRAS status. Furthermore, the oral presentation from the LGSOC Patient Impact Survey, that is supported by Verastem Oncology, highlights the negative social and emotional impact patients experience living with this rare ovarian cancer.”

Key Data Presentations:

Late-Breaking Oral Presentation

• Title: Avutometinib plus defactinib in recurrent, low-grade serous ovarian cancer: A subgroup analysis of ENGOT-ov60/GOG-3052/RAMP 201 Part A
• Session: Scientific Plenary IV: Late Breaking Abstract Session 1
• Date/Time: Sunday, March 17, 2024, 4:15 – 5:30 p.m. PDT
• Presenter: Dr. Susanna Banerjee, BBS, MA, PhD, FRCP

Focused Plenary Oral Presentation

• Title: Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low grade serous ovarian cancer
• Session: Focused Plenary V: Rare Cancer: Updates in Uncommon Cancers
• Date/Time: Sunday, March 17, 2024, 1:45 – 2:45 p.m. PDT
• Presenter: Michelle Greenman, MD, MPH

Oral Poster Presentation

• Title: Voices of women with low-grade serous ovarian cancer: Results from a multinational survey
• Session: Poster Session II
• Date/Time: Monday, March 18, 2024, 11:45 a.m. – 12:45 p.m. PDT
• Presenter: Charlotte C. Sun, DrPH, MPH

Trials in Progress Poster Presentation